A Multicenter, Randomized, Parallel Controlled, trial to Evaluate the Efficacy of Exercise Rehabilitation Therapy on Prognosis and Metabonomics in Heart Failure Patients with Preserved Ejection Fraction

INTERVENTION: Experimental group:Medication+Exercise rehabilitation;Control Group:Medication; CONDITION: Heart failure preserved with ejection fraction PRIMARY OUTCOME: 6‐minute walking test;cardiopulmonary exercise test;NT‐ProBNP;brain natriuretic peptide;cardiac color Doppler examination;eukaryotic reference transcriptome sequencing;targeted metabolomic detection; SECONDARY OUTCOME: Minnesota quality of life scale for cardiac insufficiency;Kansas City Cardiomyopathy Questionnaire;total efficacy assessment; INCLUSION CRITERIA: 1. When signing the informed consent, the subjects must be 40 years old and above; 2. Patients diagnosed with heart failure, NYHA II‐III, mainly due to outpatient consultation or hospitalization of heart failure; 3. LVEF >= 50% measured in any form within the past 12 months (at the latest at screening); if there are multiple values, the most recent value should be reported. If LVEF has not been measured in the past 12 months, a new measurement will be required during the screening period; 4. Structural cardiac abnormalities based on any local imaging measurements (last screening) within the past 12 months, defined as at least one of the following: o LAD >= 3.8 cm, LAVI > 30 mL/m2, LVMI >=115 g/m2 (?)/95 g/m2 (?), thickness of spacer or back wall >=1.1 cm, E/e'>=13; 5. NT‐proBNP>=125ng/L (BNP>=35ng/L).